A Rare Oppurtunity: IP,IT and life sciences
A concerted effort to incentivise the production of so-called orphan drugs - specialist treatment for rare medical conditions - has started to pay dividends, says, Michael Gavey
About 7,000 rare conditions have been identified for which no medical or other diagnosis, prevention or treatment is available. These so-called ‘orphan conditions’ affect some 30 million people in the European Union (EU). The pharmaceutical industry has been reluctant to develop drugs to treat them as the economics have not stacked up. Regulation (EC) No. 141/2000 on orphan medicinal products (the Orphan Regulation) was introduced in 2000 to address this problem through the establishment of a procedure for designating orphan medicinal products and the introduction of special incentives for research, development and marketing in Europe.
This premium content is reserved for
Legal Week Subscribers.
A PREMIUM SUBSCRIPTION PROVIDES:
- Trusted insight, news and analysis from the UK and across the globe
- Connections to senior business lawyers within the leading law firms and legal departments
- Unique access to ALM's unrivalled, market-leading reporting in the US and Asia and cutting-edge research, including Legal Week's UK Top 50 and Global 100 rankings
- The Legal Week Daily News Alert, Editor's Highlights, and Breaking News digital newsletters and more, plus a choice of over 70 ALM newsletters
- Optimized access on all of your devices: desktop, tablet and mobile
- Complete access to the site's full archive of more than 56,000 articles
Already have an account? Sign In Now
For enterprise-wide or corporate enquiries, please contact Paul Reeves on Preeves@alm.com or call on +44 (0) 203 875 0651